Tirzepatide 10mg

Tirzepatide is a novel, once-weekly injectable medication that has revolutionized the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is a synthetic polypeptide and a "dual agonist" for two incretin receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual agonism allows tirzepatide to mimic the effects of both natural hormones, leading to enhanced glucose-dependent insulin secretion, reduced glucagon secretion, delayed gastric emptying, and increased satiety, ultimately resulting in significant improvements in glycemic control and substantial weight loss. It is marketed under the brand names Mounjaro® for T2DM and Zepbound® for chronic weight management.

Research Applications & Benefits

• surpass-4 was a phase 3, open-label, randomized trial comparing tirzepatide (5 mg, 10 mg, or 15 mg once weekly) with insulin glargine once daily in patients with type 2 diabetes and increased cardiovascular risk whose glucose levels were inadequately controlled. the study's primary objective was to assess glycemic control, with a median follow-up of 85 weeks. tirzepatide demonstrated superior hba1c reductions and significantly greater weight loss compared to insulin glargine. importantly, tirzepatide was associated with a lower risk of hypoglycemia compared to insulin glargine. the trial also showed a numerically lower rate of major adverse cardiovascular events (mace) with tirzepatide, though it was not powered for mace superiority.

Primary Research Areas

• Type 2 Diabetes Mellitus (T2DM)
• Obesity
• Weight Management
• Glycemic Control
• HbA1c Reduction
• Cardiovascular Outcomes (CVOT)
• Non-alcoholic Steatohepatitis (NASH) / Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
• Insulin Resistance
• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonism
• Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonism
• Appetite Suppression
• Body Composition
• Renal Outcomes